SCHEMBL2964992

SCHEMBL2964992

COc1cccc(-c2ccc(C)cc2N)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.53
TDO2 P48775 1/20 0.51
MAOB P27338 2/20 0.51
ALKBH3 Q96Q83 1/20 0.49
CYP3A4 P08684 4/20 0.49
CYP1A1 P04798 2/20 0.49
CYP1A2 P05177 2/20 0.49
CYP2E1 P05181 2/20 0.49
CYP2C8 P10632 2/20 0.49
CYP2D6 P10635 2/20 0.49
CYP2A6 P11509 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP4B1 P13584 2/20 0.49
CYP2B6 P20813 2/20 0.49
CYP3A5 P20815 2/20 0.49
CYP2A7 P20853 2/20 0.49
CYP3A7 P24462 2/20 0.49
CYP2F1 P24903 2/20 0.49
CYP2C18 P33260 2/20 0.49
CYP2C19 P33261 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6011438 0.85 CYP3A4 (0.58) TDO2MAOBCYP3A4CYP1A1CYP1A2
Hydrochloric Acid SCHEMBL6011564 0.83 CYP3A4 (0.56) TDO2MAOBCYP3A4CYP1A1CYP1A2
SCHEMBL14850870 0.83 ACHE (0.57) ACHETDO2MAOBALKBH3CYP3A4
SCHEMBL4925801 0.81 CYP1A1 (0.69) ACHETDO2MAOBALKBH3CYP3A4
SCHEMBL31507403 0.81 ACHE (0.55) ACHETDO2MAOBALKBH3CYP3A4
SCHEMBL2955919 0.81 CYP3A4 (0.50) ACHEMAOBALKBH3CYP3A4CYP1A2
SCHEMBL396757 0.81 TDO2 (0.55) TDO2MAOBCYP3A4CYP1A1CYP1A2
SCHEMBL30785681 0.81 TDO2 (0.55) TDO2MAOBCYP3A4CYP1A1CYP1A2
SCHEMBL24767284 0.80 ACHE (0.53) ACHETDO2MAOBALKBH3CYP3A4
SCHEMBL277912 0.79 ACHE (0.57) ACHETDO2MAOBALKBH3CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 ACHE 3889/4885TDO2 4402/4885MAOB 3352/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 ACHE 3889/4885TDO2 4402/4885MAOB 3352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.